M&A Strategy and Due Diligence

Commercial due diligence (CDD) is the independent assessment of a target company's market attractiveness, competitive position, customer base, and growth sustainability - the analysis that ultimately validates or challenges the investment thesis behind a deal. CDD typically combines market sizing and segmentation, competitive landscape analysis, primary research with customers and industry experts, financial benchmarking, and forward-looking growth scenario modeling. The output is a defensible commercial perspective that informs valuation, deal structure, and the risks and opportunities an acquirer will inherit at close.

Commercial due diligence (CDD) is commissioned by a prospective acquirer - typically a private equity firm or strategic buyer - to independently validate the investment case before bidding or closing. Vendor due diligence (VDD) is commissioned by the seller, usually ahead of a competitive auction, to provide all bidders with a credible, independent commercial view of the asset. Both require the same analytical rigor and primary research depth, but VDD must additionally withstand scrutiny from multiple bidders and their advisors, which is why sector-specialist credibility is especially important on the sell side.

A typical CDD engagement covers market attractiveness (size, growth, structural drivers), competitive dynamics (key players, market share, differentiation, threats), customer perspective (primary research with end users, distributors, KOLs, and decision-makers), the target's commercial position and growth sustainability, and an evidence-based view on management's business plan. Most CDD projects run 4–8 weeks depending on deal complexity and geographic scope, culminating in a written report and investment committee presentation that addresses the specific questions investors and lenders need answered.

Target scouting. Sometimes called an acquisition landscape assessment, it is the systematic identification, profiling, and prioritization of potential acquisition targets within a defined sector or sub-sector. It typically begins with a clear strategic mandate (geography, size, business model, capability fit), expands into a comprehensive target universe, and progressively narrows through screening, profiling, and qualitative assessment of strategic fit. Target scouting is most valuable for sponsors pursuing buy-and-build platforms in fragmented sub-sectors such as veterinary clinics, animal diagnostics, specialty pharma, and life sciences services, where the right add-on can meaningfully accelerate value creation.

Post-acquisition value creation is the structured execution of the investment thesis after a deal closes. Translating the commercial assumptions in the deal model into measurable operational results. Common workstreams include 100-day plans, pricing transformation, sales force sizing and territory optimization, customer segmentation, multi-channel commercial model design, go-to-market acceleration, and buy-and-build integration. The objective is to compress time to value and close the gap between deal-model assumptions and operational reality, which is where sector-specialist support typically outperforms generalist alternatives.

Generic due diligence approaches frequently miss or misread the value drivers that determine deal outcomes in Animal Health and Life Sciences -species-level demand patterns, veterinary channel economics, generic erosion timelines, hospital capital cycles, payer dynamics, regulatory pathways, and KOL influence on adoption. Sector specialists bring both the analytical frameworks and the operational pattern recognition needed to surface real risks and opportunities within deal timelines. This is why an increasing share of healthcare-focused private equity firms work with specialist commercial advisors rather than generalist consulting providers for diligence on Animal Health, Life Sciences, and adjacent assets.

Most full-scope commercial due diligence engagements run 4–8 weeks from kickoff to final report, with red-flag or accelerated diligence completed in 2–3 weeks for time-pressured situations. Vendor due diligence engagements typically run 6–10 weeks, given the additional rigor required to withstand multi-bidder scrutiny. Specific timelines depend on deal complexity, geographic scope, the depth of primary research required, and the level of management access available; all of which are scoped at the start of an engagement.